Study: “Liquid Biopsy” for Detection of Residual Disease after Neoadjuvant Therapy in Breast Cancer

11 Aug, 2019 | 21:30h | UTC

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer – Science Translational Medicine (free for a limited period)

Commentaries: New ‘liquid biopsy’ blood test improves breast cancer diagnostics – The Translational Genomics Research Institute (free) AND Circulating Tumor DNA Analysis for Detection of Residual Disease in Breast Cancer – The ASCO Post (free) AND Expert reaction to blood test to help tailor treatment for breast cancer patients – Science Media Centre (free)

 

Join our WhatsApp group

Free Updates in All Specialties!

A daily update on the latest medical news, practice-changing trials and guidelines

Stay Updated in Your Specialty
No spam, just news
Unsubscribe with one click

 

Daily

 

Weekly or Less Often 
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •